Vismodegib.
Andrzej
A
Dlugosz
Sid
S
Agrawal
Peter
P
Kirkpatrick
D000813:Anilides / Q000494:pharmacology* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy; D002280:Basal Cell Carcinoma / Q000188:drug therapy / Q000473:pathology; D002986:Clinical Trials as Topic; D018795:Device Approval; D055808:Drug Discovery; D005260:Female; D053823:Hedgehog Proteins / Q000037:antagonists & inhibitors; D006801:Humans; D011725:Pyridines / Q000494:pharmacology* / Q000627:therapeutic use; D015398:Signal Transduction / Q000187:drug effects; D014481:United States; D014486:United States Food and Drug Administration
D000813:Anilides; D000970:Antineoplastic Agents; D053823:Hedgehog Proteins; C538724:HhAntag691; D011725:Pyridines